The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Patient questionnaire (VRAT) to assess ocular toxicities related to belantamab mafodotin in RRMM
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses cohort D of the ProMMise trial (ISRCTN19869915), investigating belantamab mafodotin combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma (RRMM). Dr Popat highlights that the study is exploring the use of a patient questionnaire, known as a Visual-Related Anatomist Tool (VRAT), as an alternative method of assessment for ocular toxicities. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
